WCM Investment Management LLC Acquires 247,460 Shares of Illumina, Inc. $ILMN

by · The Markets Daily

WCM Investment Management LLC grew its holdings in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 5.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,426,471 shares of the life sciences company’s stock after acquiring an additional 247,460 shares during the quarter. WCM Investment Management LLC owned 2.80% of Illumina worth $419,585,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of ILMN. Corvex Management LP increased its holdings in shares of Illumina by 125.2% in the first quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock worth $303,841,000 after acquiring an additional 2,129,449 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Illumina by 361.7% in the first quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock worth $165,484,000 after acquiring an additional 1,662,093 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Illumina by 11,714.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,161,882 shares of the life sciences company’s stock worth $92,184,000 after acquiring an additional 1,152,048 shares in the last quarter. Brown Advisory Inc. grew its holdings in shares of Illumina by 52.1% during the first quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company’s stock worth $230,818,000 after buying an additional 996,589 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Illumina by 51.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,960,385 shares of the life sciences company’s stock worth $155,537,000 after buying an additional 667,978 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Citigroup downgraded Illumina from a “hold” rating to a “strong sell” rating and decreased their price objective for the stock from $85.00 to $80.00 in a report on Wednesday, July 9th. Robert W. Baird increased their price objective on Illumina from $84.00 to $105.00 and gave the stock a “neutral” rating in a report on Monday, July 28th. Canaccord Genuity Group increased their price objective on Illumina from $99.00 to $105.00 and gave the stock a “hold” rating in a report on Friday, August 1st. Stephens set a $110.00 price objective on Illumina and gave the stock an “overweight” rating in a report on Monday, August 4th. Finally, Wall Street Zen downgraded Illumina from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Six equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average price target of $123.56.

Get Our Latest Stock Analysis on Illumina

Illumina Stock Up 2.2%

ILMN stock opened at $93.00 on Thursday. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The business has a 50 day moving average price of $98.10 and a two-hundred day moving average price of $90.44. The company has a market cap of $14.29 billion, a price-to-earnings ratio of 11.77, a P/E/G ratio of 2.19 and a beta of 1.40. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business’s revenue was down 4.8% compared to the same quarter last year. During the same period last year, the company earned $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Further Reading